Matej Mikulic
Research expert covering health, pharma & medtech
Pharmaceutical research and development (R&D) – statistics & facts
Global pharmaceutical R&D spending has nearly doubled since 2016, reaching around 300 billion U.S. dollars in 2025, and projections point to continued but modest expansion through 2030. Annual spending growth has consistently decelerated, settling at just 1.7 percent in recent years — suggesting the industry has entered a consolidation phase rather than a new investment cycle. The baseline has simply grown large enough that sustaining high growth rates has become structurally harder. Regional dynamics reinforce this shift: China expanded its R&D spending at over 16 percent annually between 2020 and 2024, far outpacing both Europe at around eight and the U.S. at some four percent over the same period. China now accounts for almost one fifth of all companies with active pipelines globally. This divergence points to a structural rebalancing of where pharmaceutical innovation capacity is being built — with implications for long-term competitive positioning between regions.Â
Scale masks a deepening concentration risk
The sheer scale of the global pipeline is striking: the number of drugs in development has grown nearly fourfold since 2001, approaching 23,000 in 2026, supported by over 7,000 companies with active pipelines. This expansion is not arbitrary — oncology, as one of the leading causes of death globally, commands a correspondingly large share of R&D attention. Yet the degree of concentration goes beyond what disease burden alone would explain. Immunological anticancer products account for nearly 4,900 pipeline candidates, more than four times the next-largest therapeutic category, and immuno-oncology compounds represent the leading mechanism of action by a wide margin. This points to a growing structural dependency on a single therapeutic area — one that amplifies the industry's collective exposure to clinical and regulatory setbacks within oncology.
The productivity gap widens
The industry's fundamental challenge is not a lack of ambition but a widening gap between input and output. In 2024, the average clinical trial cycle extended to over 100 months for the first time, up from 93 months four years earlier, while the probability of a drug reaching approval from Phase I remains in the low single digits for oncology — the most heavily funded area. The modality shift toward biologics, gene therapies, and cell-based treatments, while scientifically promising, compounds this dynamic: these approaches carry higher development complexity, longer timelines, and elevated manufacturing demands. Together, these forces point to a structural productivity constraint that spending growth alone cannot overcome.
Strategic Outlook
The tension between expanding pipelines and compressing returns has defined pharmaceutical R&D for much of the past decade, but recent data points to a cautious inflection. The forecast internal rate of return for the top 20 biopharma companies rose to seven percent in 2025 — a second consecutive year of improvement — with the recovery driven largely by GLP-1 and metabolic disease assets advancing into late-stage development. This improvement, however, has been characterized as fragile: progress remains narrowly concentrated in a small number of therapeutic bets rather than reflecting a broad-based productivity recovery across the pipeline.Â
This fragility matters because it mirrors the concentration pattern visible in the pipeline data itself. Investment and dealmaking are increasingly directed toward high-value science and a smaller number of emerging biopharma platforms, suggesting the industry is converging on fewer, higher-conviction programs as a response to the productivity challenge. Whether this represents a sustainable path to improved returns — or simply defers the underlying structural tension — will likely depend on the extent to which next-generation modalities and emerging therapeutic areas can develop into credible new growth engines beyond the current GLP-1 wave.
